Insurance, Pharmaceutical Services
"Insurance, Pharmaceutical Services" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insurance providing for payment of services rendered by the pharmacist. Services include the preparation and distribution of medical products.
| Descriptor ID |
D007356
|
| MeSH Number(s) |
N03.219.521.576.343.575
|
| Concept/Terms |
Insurance, Pharmaceutical Services- Insurance, Pharmaceutical Services
- Pharmacy Services Insurance
- Pharmaceutic Services Insurance
- Pharmaceutical Services Insurance
- Insurance, Pharmaceutic Services
- Insurance, Pharmacy Services
Drug Benefit Plans- Drug Benefit Plans
- Drug Benefit Plan
- Plan, Drug Benefit
- Plans, Drug Benefit
|
Below are MeSH descriptors whose meaning is more general than "Insurance, Pharmaceutical Services".
Below are MeSH descriptors whose meaning is more specific than "Insurance, Pharmaceutical Services".
This graph shows the total number of publications written about "Insurance, Pharmaceutical Services" by people in this website by year, and whether "Insurance, Pharmaceutical Services" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 4 | 1 | 5 |
| 2019 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Insurance, Pharmaceutical Services" by people in Profiles.
-
Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims. PLoS One. 2021; 16(4):e0249453.
-
COVID-19 pandemic and antiretrovirals (ARV) availability in Nigeria: recommendations to prevent shortages. Pan Afr Med J. 2020; 35(Suppl 2):149.
-
Older adults' strategies for obtaining medication refills in hypothetical scenarios in the face of COVID-19 risk. J Am Pharm Assoc (2003). 2020 Nov - Dec; 60(6):915-922.e4.
-
An early look at where the federal parties stand on health care. CMAJ. 2019 07 22; 191(29):E826-E827.
-
Pharmacy Benefit Managers: Practices, Controversies, and What Lies Ahead. Issue Brief (Commonw Fund). 2019 Mar 01; 2019:1-11.
-
Massachusetts' Proposed Medicaid Reforms - Cheaper Drugs and Better Coverage? N Engl J Med. 2018 Jan 11; 378(2):109-111.
-
Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA. 2017 08 15; 318(7):609-610.
-
Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis. Pain Med. 2017 06 01; 18(6):1019-1026.
-
Accelerated Approval and Expensive Drugs - A Challenging Combination. N Engl J Med. 2017 May 25; 376(21):2001-2004.
-
Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015. PLoS One. 2017; 12(5):e0176420.